Merck's (MRK) odanacatib osteoporosis drug significantly increased hip and spine bone mineral...

|About: Merck & Co Inc. (MRK)|By:, SA News Editor

Merck's (MRK) odanacatib osteoporosis drug significantly increased hip and spine bone mineral density in a phase two trial of post-menopausal women who had previously taken the company's Fosamax treatment. "Odanacatib may be a viable alternative for patients who need continued therapy and who want benefits beyond what they (already) received," Merck said. (PR)